Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics

BACKGROUND: Compared with younger patients, older adults with acute myeloid leukemia (AML) generally have poorer survival outcomes and less benefit from clinical trials. A recent phase 3 trial demonstrated a trend toward improved overall survival (OS) with decitabine, a hypomethylating agent, compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer, Jiří, Arthur, Christopher, Delaunay, Jacques, Mazur, Grzegorz, Thomas, Xavier G, Wierzbowska, Agnieszka, Ravandi, Farhad, Berrak, Erhan, Jones, Mark, Li, Yuhan, Kantarjian, Hagop M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928608/
https://www.ncbi.nlm.nih.gov/pubmed/24498872
http://dx.doi.org/10.1186/1471-2407-14-69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928608/
https://www.ncbi.nlm.nih.gov/pubmed/24498872
http://dx.doi.org/10.1186/1471-2407-14-69

Ejemplares similares